Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study

Area of Science:

• Biochemistry
• Oncology
• Metabolomics

Background:

• Cachexia affects 50-80% of cancer patients, presenting as reduced food intake and abnormal metabolism.
• Systemic inflammation and negative protein/energy balance characterize cachexia's pathophysiology.
• Current diagnostic criteria and treatments for cachexia remain limited.

Purpose of the Study:

• To investigate blood-based metabolomics for insights into cancer cachexia pathophysiology.
• To identify potential biomarkers for cachexia diagnosis and therapeutic targets.
• To explore novel therapeutic strategies based on metabolomic findings.

Main Methods:

• Cross-sectional observational study comparing cachectic and non-cachectic cancer patients.
• Blood metabolite fingerprinting using GC-MS, CE-MS, and LC-MS.
• Pathway-based metabolite analyses to understand biological functions.

Main Results:

• Metabolomic analyses accurately classified cachectic vs. non-cachectic samples (80-97% accuracy).
• Cachectic patients showed decreased plasma amino acids (e.g., arginine, tryptophan) and lipids (e.g., lysophosphatidylcholines, sphingolipids).
• Elevated cortisol levels were observed in cachectic patients, alongside alterations in amino acid and lipid metabolism pathways.

Conclusions:

• Plasma amino acid and lipid profiling shows promise for understanding cachexia pathogenesis.
• Metabolic differences in plasma correlate with cachexia pathophysiology.
• Further understanding may lead to novel therapeutic approaches for cancer cachexia.